ProBioGen’s growth strategy continues successfully
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
This order is subject to initial advance payment as per the agreed terms of the contract
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
Subscribe To Our Newsletter & Stay Updated